MBNL2

Summary

MBNL2 (muscleblind like splicing regulator 2, HGNC:16746) is a protein-coding gene on chromosome 13q32.1, encoding Muscleblind-like protein 2 (Q5VZF2). Mediates pre-mRNA alternative splicing regulation.

This gene is a member of the muscleblind protein family which was initially described in Drosophila melanogaster. This gene encodes a C3H-type zinc finger protein that modulates alternative splicing of pre-mRNAs. Muscleblind proteins bind specifically to expanded dsCUG RNA but not to normal size CUG repeats and may thereby play a role in the pathophysiology of myotonic dystrophy. Several alternatively spliced transcript variants have been described but the full-length natures of only some have been determined.

Source: NCBI Gene 10150 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 36 total
• MANE Select transcript: NM_001382683

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16746
Approved symbol	MBNL2
Name	muscleblind like splicing regulator 2
Location	13q32.1
Locus type	gene with protein product
Status	Approved
Aliases	MBLL, MBLL39
Ensembl gene	ENSG00000139793
Ensembl biotype	protein_coding
OMIM	607327
Entrez	10150

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 20 protein_coding, 1 nonsense_mediated_decay

ENST00000343600, ENST00000345429, ENST00000376673, ENST00000397601, ENST00000449284, ENST00000469707, ENST00000679496, ENST00000685165, ENST00000692685, ENST00000704364, ENST00000704373, ENST00000899849, ENST00000899850, ENST00000899851, ENST00000899852, ENST00000899853, ENST00000899854, ENST00000899855, ENST00000944724, ENST00000944725, ENST00000944726

RefSeq mRNA: 45 — MANE Select: NM_001382683 NM_001306070, NM_001382649, NM_001382650, NM_001382651, NM_001382652, NM_001382653, NM_001382654, NM_001382656, NM_001382660, NM_001382661, NM_001382663, NM_001382666, NM_001382667, NM_001382668, NM_001382669, NM_001382670, NM_001382671, NM_001382672, NM_001382673, NM_001382674, NM_001382675, NM_001382676, NM_001382677, NM_001382678, NM_001382679, NM_001382680, NM_001382681, NM_001382682, NM_001382683, NM_001382684, NM_001382685, NM_001382686, NM_001382687, NM_001382688, NM_001382689, NM_001382690, NM_001382691, NM_001382692, NM_001382693, NM_001382694, NM_001382695, NM_001382696, NM_001382697, NM_144778, NM_207304

CCDS: CCDS76644, CCDS91823, CCDS91824, CCDS91825, CCDS9483, CCDS9484

Canonical transcript exons

ENST00000679496 — 9 exons

Exon	Start	End
ENSE00001366583	97346804	97347067
ENSE00001654828	97343016	97343216
ENSE00001719168	97334276	97334440
ENSE00002718246	97275632	97276409
ENSE00003541358	97357482	97357635
ENSE00003639197	97391322	97394120
ENSE00003915428	97222333	97222531
ENSE00003991510	97365136	97365171
ENSE00003991542	97356796	97356849

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 60.3827 / max 1519.6763, expressed in 1778 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
135720	57.4061	1775
135718	1.5266	399
135722	0.4801	243
135723	0.4183	151
135726	0.2443	105
135724	0.1308	27
135733	0.0812	26
135721	0.0620	14
135725	0.0333	10

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	99.18	gold quality
lateral globus pallidus	UBERON:0002476	98.50	gold quality
heart right ventricle	UBERON:0002080	98.44	gold quality
inferior vagus X ganglion	UBERON:0005363	98.43	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.35	gold quality
subthalamic nucleus	UBERON:0001906	98.34	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.29	gold quality
pons	UBERON:0000988	98.26	gold quality
substantia nigra pars compacta	UBERON:0001965	98.14	gold quality
cranial nerve II	UBERON:0000941	98.03	gold quality
corpus callosum	UBERON:0002336	97.98	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.94	gold quality
biceps brachii	UBERON:0001507	97.87	gold quality
inferior olivary complex	UBERON:0002127	97.81	gold quality
superficial temporal artery	UBERON:0001614	97.60	gold quality
medulla oblongata	UBERON:0001896	97.60	gold quality
Brodmann (1909) area 23	UBERON:0013554	97.40	gold quality
postcentral gyrus	UBERON:0002581	97.38	gold quality
superior vestibular nucleus	UBERON:0007227	97.36	gold quality
parietal lobe	UBERON:0001872	97.34	gold quality
periodontal ligament	UBERON:0008266	97.15	gold quality
CA1 field of hippocampus	UBERON:0003881	97.12	gold quality
cauda epididymis	UBERON:0004360	97.01	gold quality
calcaneal tendon	UBERON:0003701	96.98	gold quality
ventral tegmental area	UBERON:0002691	96.91	gold quality
dorsal plus ventral thalamus	UBERON:0001897	96.83	gold quality
saphenous vein	UBERON:0007318	96.81	gold quality
entorhinal cortex	UBERON:0002728	96.69	gold quality
seminal vesicle	UBERON:0000998	96.60	gold quality
occipital lobe	UBERON:0002021	96.58	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.04
E-CURD-10	no	497.63
E-GEOD-81608	no	4.67

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA3

miRNA regulators (miRDB)

348 targeting MBNL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4262	100.00	73.26	3931
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-7110-3P	100.00	73.18	2486

Literature-anchored findings (GeneRIF, showing 12)

• MBNL proteins promote opposite splicing patterns for cardiac troponin T and insulin receptor alternative exons (PMID:15257297)
• MBNL1 and MBNL2 always co-distributed. Functional differences between MBNL1 and MBNL2 have not yet been found (PMID:19095965)
• solution structures of both tandem zinc finger (TZF) motifs, TZF12 (comprising ZF1 and ZF2) and TZF34 (ZF3 and ZF4), in MBNL2 (PMID:19177353)
• We propose that major pathological features of the myotonic dystrophy brain result from disruption of the MBNL2-mediated developmental splicing program (PMID:22884328)
• consistent with a central and negative regulatory role for MBNL proteins in pluripotency, their knockdown significantly enhances the expression of key pluripotency genes and the formation of induced pluripotent stem cells during somatic cell reprogramming (PMID:23739326)
• both MBNL1 and MBNL2 are involved in the regulation of Tau exon 2 splicing and the mis-splicing of Tau in DM1 is due to the combined inactivation of both (PMID:24440524)
• Sense DMPK RNA foci clearly co-localize with MBNL1 and MBNL2 proteins and accumulate in myotonic dystrophy 1 tissues during development. (PMID:26339785)
• Low MBNL2 expression is associated with hepatocellular carcinoma growth and invasion. (PMID:27564110)
• Functional depletion of the alternative splicing factors Muscleblind-like (MBNL 1 and 2) is at the basis of the neuromuscular disease myotonic dystrophy type 1 (DM1). Here, we screen for miRNAs that regulate MBNL1 and MBNL2 in HeLa cells. We thus identify miR-23b and miR-218, and confirm that they downregulate MBNL proteins in this cell line. (PMID:29946070)
• MBNL2 induction was critical for hypoxia adaptation by controlling the transcript abundance of hypoxia response genes, such as vascular endothelial growth factor A (VEGFA) MBNL2 depletion reduced the proliferation and migration of cancer cells, demonstrating an important role of MBNL2 as cancer driver. (PMID:32127384)
• SNPs in SNCA, MCCC1, DLG2, GBF1 and MBNL2 are associated with Parkinson’s disease in southern Chinese population. (PMID:32652860)
• MBNL2 Regulates DNA Damage Response via Stabilizing p21. (PMID:33466733)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mbnl2	ENSDARG00000018460
mus_musculus	Mbnl2	ENSMUSG00000022139
rattus_norvegicus	Mbnl2	ENSRNOG00000010737
drosophila_melanogaster	mbl	FBGN0265487
caenorhabditis_elegans		WBGENE00019347

Paralogs (3): MBNL3 (ENSG00000076770), ZC3H10 (ENSG00000135482), MBNL1 (ENSG00000152601)

Protein

Protein identifiers

Muscleblind-like protein 2 — Q5VZF2 (reviewed: Q5VZF2)

Alternative names: Muscleblind-like protein 1, Muscleblind-like protein-like, Muscleblind-like protein-like 39

All UniProt accessions (9): Q5VZF2, A0A7P0T9I3, A0A8I5KU79, A0A8I5KYZ5, A0A994J506, A0A994J509, A2A3S3, O95205, Q5JSC0

UniProt curated annotations — full annotation on UniProt →

Function. Mediates pre-mRNA alternative splicing regulation. Acts either as activator or repressor of splicing on specific pre-mRNA targets. Inhibits cardiac troponin-T (TNNT2) pre-mRNA exon inclusion but induces insulin receptor (IR) pre-mRNA exon inclusion in muscle. Antagonizes the alternative splicing activity pattern of CELF proteins. RNA-binding protein that binds to 5’ACACCC-3’ core sequence, termed zipcode, within the 3’UTR of ITGA3. Binds to CUG triplet repeat expansion in myotonic dystrophy muscle cells by sequestering the target RNAs. Together with RNA binding proteins RBPMS and RBFOX2, activates vascular smooth muscle cells alternative splicing events. Regulates NCOR2 alternative splicing. Seems to regulate expression and localization of ITGA3 by transporting it from the nucleus to cytoplasm at adhesion plaques. May play a role in myotonic dystrophy pathophysiology (DM).

Subunit / interactions. Interacts with ITGA3.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Similarity. Belongs to the muscleblind family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q5VZF2-1	1	yes
Q5VZF2-2	2
Q5VZF2-3	3

RefSeq proteins (45): NP_001292999, NP_001369578, NP_001369579, NP_001369580, NP_001369581, NP_001369582, NP_001369583, NP_001369585, NP_001369589, NP_001369590, NP_001369592, NP_001369595, NP_001369596, NP_001369597, NP_001369598, NP_001369599, NP_001369600, NP_001369601, NP_001369602, NP_001369603, NP_001369604, NP_001369605, NP_001369606, NP_001369607, NP_001369608, NP_001369609, NP_001369610, NP_001369611, NP_001369612, NP_001369613, NP_001369614, NP_001369615, NP_001369616, NP_001369617, NP_001369618, NP_001369619, NP_001369620, NP_001369621, NP_001369622, NP_001369623, NP_001369624, NP_001369625, NP_001369626, NP_659002, NP_997187 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000571	Znf_CCCH	Domain
IPR054429	Znf-CCCH_Muscleblind-like	Domain

Pfam: PF00642, PF22628

UniProt features (24 total): strand 7, helix 7, zinc finger region 4, turn 2, splice variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2E5S	SOLUTION NMR
2RPP	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VZF2-F1	65.76	0.24

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 379 (showing top): ATF_B, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, MULLIGHAN_NPM1_SIGNATURE_3_UP, FREAC2_01, FISCHER_G1_S_CELL_CYCLE, NKX25_02, AMIT_EGF_RESPONSE_60_HELA, GCANCTGNY_MYOD_Q6, TTTGTAG_MIR520D, TATTATA_MIR374, TAL1ALPHAE47_01, HNF1_Q6, CAGCTG_AP4_Q5, NKX61_01, CREB_Q4

GO Biological Process (3): mRNA processing (GO:0006397), RNA splicing (GO:0008380), regulation of RNA splicing (GO:0043484)

GO Molecular Function (5): RNA binding (GO:0003723), zinc ion binding (GO:0008270), sequence-specific double-stranded DNA binding (GO:1990837), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
cellular anatomical structure	2
mRNA metabolic process	1
RNA splicing	1
regulation of gene expression	1
regulation of primary metabolic process	1
nucleic acid binding	1
transition metal ion binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
binding	1
cation binding	1
nuclear lumen	1
intracellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1114 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MBNL2	CNBP	P20694	972
MBNL2	CELF1	Q92879	906
MBNL2	CLCN1	P35523	901
MBNL2	QKI	Q96PU8	890
MBNL2	DMPK	Q09013	850
MBNL2	MBNL3	Q9NUK0	646
MBNL2	CELF2	O95319	646
MBNL2	CELF3	Q5SZQ8	617
MBNL2	RBFOX2	O43251	607
MBNL2	ADAR	P55265	603
MBNL2	CEBPD	P49716	598
MBNL2	ZNF609	O15014	592
MBNL2	ATP2A1	O14983	585
MBNL2	MBNL1	Q9NR56	581
MBNL2	RBFOX1	Q9NWB1	576

IntAct

4 interactions, top by confidence:

A	B	Type	Score
MBNL2	ACOX1	psi-mi:“MI:0915”(physical association)	0.400
MBNL1	MBNL2	psi-mi:“MI:0914”(association)	0.350
MBNL2	prmC	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (38): MBNL2 (Affinity Capture-RNA), MBNL2 (Affinity Capture-RNA), MBNL2 (Affinity Capture-MS), MBNL2 (Affinity Capture-MS), MBNL2 (Affinity Capture-MS), ACOX1 (Affinity Capture-MS), MBNL2 (Affinity Capture-MS), MBNL2 (Affinity Capture-MS), ACOX1 (Affinity Capture-MS), MBNL2 (Affinity Capture-RNA), MBNL2 (Two-hybrid), TIAL1 (Two-hybrid), MBNL2 (Proximity Label-MS), MBNL2 (Proximity Label-MS), MBNL2 (Proximity Label-MS)

ESM2 similar proteins: A0A8I6B1J2, A0AV96, A8XND8, B3M3R5, B3NGA1, B4HUE4, B4IX08, B4KX02, B4LFQ9, B4MM23, B4PIS2, B4QRJ0, F2Z3T4, G5EFF1, O01367, P16914, P31367, Q0V9L3, Q24312, Q32NN2, Q56V19, Q5R4F5, Q5R5P4, Q5VZF2, Q5W9D5, Q5W9D6, Q5W9D7, Q5ZKW9, Q66H68, Q6IRN2, Q6P0D0, Q6P104, Q6Q2B2, Q7JJZ8, Q7TSY6, Q8C181, Q8MSV2, Q8R003, Q8R205, Q91WT8

Diamond homologs: A0A8I6B1J2, A8XND8, F2Z3T4, O16011, Q0JD07, Q56V19, Q5R4F5, Q5VZF2, Q5ZKW9, Q6Q2B2, Q8C181, Q8R003, Q94250, Q9JKP5, Q9NR56, Q9NUK0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2171 predictions. Top by Δscore:

Variant	Effect	Δscore
13:97334270:TTACA:T	acceptor_loss	1.0000
13:97334271:TACA:T	acceptor_loss	1.0000
13:97334273:CA:C	acceptor_loss	1.0000
13:97334274:A:AG	acceptor_gain	1.0000
13:97334274:AG:A	acceptor_gain	1.0000
13:97334274:AGG:A	acceptor_gain	1.0000
13:97334275:G:A	acceptor_loss	1.0000
13:97334275:G:GA	acceptor_gain	1.0000
13:97334275:GG:G	acceptor_gain	1.0000
13:97334275:GGG:G	acceptor_gain	1.0000
13:97334275:GGGCC:G	acceptor_gain	1.0000
13:97334436:CAGTG:C	donor_gain	1.0000
13:97334438:GTG:G	donor_gain	1.0000
13:97334439:TGG:T	donor_loss	1.0000
13:97334441:G:C	donor_loss	1.0000
13:97334441:G:GG	donor_gain	1.0000
13:97334442:TGA:T	donor_loss	1.0000
13:97334443:GAG:G	donor_loss	1.0000
13:97334444:AGTA:A	donor_loss	1.0000
13:97343214:G:GT	donor_gain	1.0000
13:97347065:ATGG:A	donor_loss	1.0000
13:97347066:TGGTA:T	donor_loss	1.0000
13:97347068:GTA:G	donor_loss	1.0000
13:97347069:T:G	donor_loss	1.0000
13:97356685:A:AG	acceptor_gain	1.0000
13:97356685:AAT:A	acceptor_gain	1.0000
13:97357477:TCTA:T	acceptor_loss	1.0000
13:97357478:CTAG:C	acceptor_loss	1.0000
13:97357480:A:AG	acceptor_gain	1.0000
13:97357480:A:C	acceptor_loss	1.0000

AlphaMissense

2558 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:97276272:T:A	W13R	1.000
13:97276272:T:C	W13R	1.000
13:97276273:G:C	W13S	1.000
13:97276274:G:C	W13C	1.000
13:97276274:G:T	W13C	1.000
13:97276276:T:A	L14Q	1.000
13:97276276:T:C	L14P	1.000
13:97276284:G:A	E17K	1.000
13:97276288:T:A	V18D	1.000
13:97276290:T:A	C19S	1.000
13:97276290:T:C	C19R	1.000
13:97276291:G:A	C19Y	1.000
13:97276291:G:C	C19S	1.000
13:97276291:G:T	C19F	1.000
13:97276292:C:G	C19W	1.000
13:97276294:G:C	R20T	1.000
13:97276294:G:T	R20I	1.000
13:97276295:A:C	R20S	1.000
13:97276295:A:T	R20S	1.000
13:97276314:T:A	C27S	1.000
13:97276314:T:C	C27R	1.000
13:97276315:G:A	C27Y	1.000
13:97276315:G:C	C27S	1.000
13:97276315:G:T	C27F	1.000
13:97276316:C:G	C27W	1.000
13:97276335:T:A	C34S	1.000
13:97276335:T:C	C34R	1.000
13:97276336:G:A	C34Y	1.000
13:97276336:G:C	C34S	1.000
13:97276336:G:T	C34F	1.000

dbSNP variants (sampled 300 via entrez): RS1000000735 (13:97141693 T>C), RS1000027850 (13:97364402 A>T), RS1000028168 (13:97150243 G>A), RS1000037784 (13:97270299 TATTA>T), RS1000037822 (13:97222287 A>G), RS1000057248 (13:97143758 A>G), RS1000060086 (13:97254498 C>T), RS1000081969 (13:97367080 C>T), RS1000084440 (13:97312996 T>C), RS1000086735 (13:97319801 G>A), RS1000093012 (13:97354067 C>T), RS1000094178 (13:97193460 A>T), RS1000118977 (13:97302822 C>A), RS1000128355 (13:97233033 T>A), RS1000185613 (13:97264058 G>A)

Disease associations

OMIM: gene MIM:607327 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001053_5	Alcoholism (alcohol use disorder factor score)	2.000000e-06
GCST001054_4	Alcoholism (alcohol dependence factor score)	8.000000e-07
GCST001762_447	Obesity-related traits	6.000000e-06
GCST004524_1	Energy expenditure (24h)	6.000000e-07
GCST004524_4	Energy expenditure (24h)	4.000000e-06
GCST006630_41	Diastolic blood pressure	4.000000e-13
GCST006940_179	Neurociticism	2.000000e-08
GCST008661_1	Lung function in heavy smokers (high FEV1 vs average FEV1)	1.000000e-07
GCST008758_89	Pre-treatment viral load in HIV-1 infection	3.000000e-18
GCST009325_14	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	1.000000e-09
GCST010485_3	Platelet reactivity in response to clopidogrel treatment	6.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005108	arm span
EFO:0006336	diastolic blood pressure
EFO:0007660	neuroticism measurement
EFO:0004314	forced expiratory volume
EFO:0010125	viral load

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

82 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, increases expression, affects expression	4
sodium arsenite	affects cotreatment, increases abundance, increases expression, decreases expression	4
Valproic Acid	affects cotreatment, increases expression, decreases expression	4
Arsenic	increases expression, affects cotreatment, decreases expression, increases methylation, increases abundance	3
Benzo(a)pyrene	increases expression, affects methylation, decreases expression	3
Cyclosporine	increases expression	3
bisphenol A	affects cotreatment, decreases methylation, increases expression	2
entinostat	decreases expression, affects cotreatment	2
Air Pollutants	decreases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cadmium Chloride	increases expression	2
aristolochic acid I	decreases expression	1
geldanamycin	increases expression	1
testosterone enanthate	affects expression	1
methylmercuric chloride	decreases expression, increases expression	1
triphenyl phosphate	affects expression	1
methylselenic acid	increases expression	1
sodium arsenate	increases abundance, increases expression	1
nickel chloride	increases expression	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine	increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
chromium hexavalent ion	increases abundance, increases expression	1
pentabromodiphenyl ether	increases expression	1
CGP 52608	affects binding, increases reaction	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.